Earlier this year, we picked apart the 23andMe stock offering for genetic testing. The financial picture looked stagnant, with 23andMe (ME) trying to build interest in the company’s FDA-authorized health insights and a subscription service that provides access to additional reports as they become available. As we noted in the article, the company’s most valuable […]
With more than 9,700 hedge funds in operation around the planet, it’s highly unlikely that a handful of amateur stock manipulators on Reddit are bringing down Wall Street. It’s a myth that the media continues to perpetuate, further exacerbating the problem by encouraging even more dumb money to enter the fracas. What you are seeing […]
Earlier this month, Alphabet (GOOG) took the air out of its Loon subsidiary, a former moonshot project for deploying internet around the world using high-flying balloons. Apparently, the economics just didn’t work out. No word on how much Google’s parent company spent on Loon, but SoftBank had sunk $125 million into the business in 2019. […]
Fewer than half of Americans own a passport. Some say that’s because their own backyard is such a big one. The half of our audience that hails from there may not be aware of what’s happening with global travel because they’re blissfully watching the stock market soar inexplicably. According to the World Tourism Barometer, international […]
We research and write about tech companies and stocks religiously, but we’ve learned the hard way that trying to cherry-pick winning stocks is a high-risk game. No matter how promising the thesis, every company can potentially implode. In an attempt to weed out the land mines, we look for companies with strong industry partnerships (as […]
Investors in Illumina must be stoked about how things have been going so far for a company that commands a dominant market share in one of the most transformative technologies of our time – genetic sequencing. It’s allowed us to pursue promising technologies like gene editing – and now base editing – which means we can start […]
You probably don’t know much about rare diseases unless you’re one of the unfortunate few who are afflicted by one. Not everyone agrees upon how we ought to define a rare disease, but in the United States, that’s considered one that affects less than 200,000 people or about 1 in 1,636 people. While some diseases […]
The history of direct-to-consumer genomics tests goes something like this. Genomics startups first started offering hereditary tests that required a DNA sample and everyone quickly climbed on board without realizing just how much information they were handing over to people they didn’t really know that well. Eventually, testing companies started moving into DNA health tests and then the FDA […]
It’s a dog-eat-dog world when it comes to DNA testing. We’ve seen it all over the last few years, from serious topics such as privacy issues and the ethics of DNA testing for intelligence to super silly applications like physical fitness and dating. It’s certainly an industry that has courted its share of controversy, with companies […]
We’re well into 2019, which means most of us have already given up on our New Year’s resolution to get back into shape. That is not our typically cynical but witty intro to the topic of personal trainer apps for getting into shape. There is a bit of science that says that most of us […]